US · ZCMD · MEDICAL - HEALTHCARE INFORMATION SERVICES
Zhongchao Inc. (ZCMD) intrinsic value and stock valuation
$0.78as of 2026-11-21 · Mkt cap 40.98K
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Zhongchao Inc. DCF and intrinsic value
InvestorsCraft values ZCMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ZCMD’s statements →
Zhongchao Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $11.4M | $15.9M | $19.4M | $14.2M | $16.3M |
| Operating income | -$-6.19M | -$-340K | -$-13.28M | -$-2.95M | -$-320K |
| Net income | -$-6.31M | -$-640K | -$-11.34M | -$-2.94M | $240K |
| EPSd | -$-157.75M | -$-64M | — | — | — |
| Operating cash flow | $850K | -$-1.47M | $50K | -$-660K | $2.86M |
| Capital expenditure | -$-150K | -$-3.05M | -$-840K | -$-1.86M | -$-1.8M |
| Free cash flow | $690K | -$-4.52M | -$-790K | -$-2.52M | $1.06M |
| Total assets | $24.3M | $25.9M | $24.4M | $38.6M | $36.3M |
| Total debt | $30K | $60K | $810K | $1.7M | $200K |
| Net debt | -$-8.07M | -$-7.78M | -$-6.74M | -$-9.82M | -$-13.71M |
| Total equity | $22.6M | $24.2M | $21M | $33M | $32.6M |
| Cash and short-term investments | $13.9M | $13.1M | $13.5M | $12M | $14.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $11.4M | $15.9M | $19.4M | $14.2M | $16.3M |
| Cost of revenue | $6.54M | $6.95M | $10.9M | $7.79M | $6.86M |
| Gross profit | $4.83M | $8.91M | $8.51M | $6.36M | $9.44M |
| Research and development expenses | $10K | $250K | $510K | $410K | $760K |
| Selling, general and administrative expenses | $11M | $9M | $13.4M | $8.9M | $9M |
| Other expenses | $0.00 | $0.00 | $7.87M | $0.00 | $0.00 |
| Operating expenses | $11M | $9.25M | $21.8M | $9.31M | $9.76M |
| Cost and expenses | $17.6M | $16.2M | $32.7M | $17.1M | $16.6M |
| Interest income | $340K | $240K | $240K | $140K | $180K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $320K | $430K | $920K | $730K | $700K |
| Ebitda | -$-5.45M | $90K | -$-4.49M | -$-1.82M | $590K |
| Operating income | -$-6.19M | -$-340K | -$-13.28M | -$-2.95M | -$-320K |
| Total other income/expenses, net | $420K | $400K | $1.31M | $400K | $210K |
| Income before tax | -$-5.77M | $60K | -$-11.98M | -$-2.55M | -$-110K |
| Income tax expense | $50K | $340K | -$-670K | $270K | -$-350K |
| Net income | -$-6.31M | -$-640K | -$-11.34M | -$-2.94M | $240K |
| Weighted average shares outstanding | $40K | $10K | $0.00 | $0.00 | $0.00 |
| Weighted average diluted shares outstanding | $40K | $10K | $0.00 | $0.00 | $0.00 |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $13.9M | $13.1M | $13.5M | $12M | $14.2M |
| Net receivables | $2.88M | $4.78M | $3.02M | $9.13M | $12.4M |
| Inventory | $0.00 | $590K | $590K | $190K | $0.00 |
| Total current assets | $17M | $18.7M | $18.7M | $22.7M | $27.3M |
| Property, plant and equipment, net | $5.9M | $5.96M | $4.02M | $5.8M | $4.31M |
| Goodwill and intangible assets | $10K | $10K | $20K | $6.98M | $380K |
| Long-term investments | $1.23M | $1.09M | $1.31M | $1.26M | $2.14M |
| Total non-current assets | $7.35M | $7.18M | $5.71M | $15.9M | $9.01M |
| Total assets | $24.3M | $25.9M | $24.4M | $38.6M | $36.3M |
| Accounts payable | $530K | $540K | $680K | $140K | $40K |
| Short-term debt | $30K | $30K | $240K | $480K | $90K |
| Deferred revenue | $150K | $200K | $840K | $400K | $10K |
| Total current liabilities | $1.53M | $1.53M | $2.68M | $4.17M | $3.59M |
| Long-term debt | $0.00 | $20K | $570K | $1.22M | $110K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $190K | $200K | $700K | $1.43M | $110K |
| Capital lease obligations | $30K | $60K | $810K | $1.7M | $200K |
| Total liabilities | $1.72M | $1.73M | $3.38M | $5.6M | $3.7M |
| Common stock | $30K | $30K | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-14.19M | -$-7.96M | -$-7.27M | $4.12M | $7.18M |
| Accumulated other comprehensive income (loss) | -$-1.69M | -$-290K | $140K | $800K | $2.4M |
| Total equity | $22.6M | $24.2M | $21M | $33M | $32.6M |
| Total investments | $7.06M | $6.33M | $7.21M | $1.78M | $2.44M |
| Total debt | $30K | $60K | $810K | $1.7M | $200K |
| Net debt | -$-8.07M | -$-7.78M | -$-6.74M | -$-9.82M | -$-13.71M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-6.31M | -$-270K | -$-11.31M | -$-2.82M | $240K |
| Depreciation and amortization | $320K | $430K | $920K | $730K | $700K |
| Stock-based compensation | $0.00 | $110K | $140K | $160K | $210K |
| Change in working capital | $1.82M | -$-2M | $2.69M | $170K | $1.53M |
| Accounts receivable | $1.17M | -$-2.32M | $2.79M | $1.08M | -$-100K |
| Inventory | $600K | -$-10K | -$-410K | -$-190K | $0.00 |
| Accounts payable | -$-30K | -$-130K | $550K | $100K | -$-380K |
| Net cash provided by operating activities | $850K | -$-1.47M | $50K | -$-660K | $2.86M |
| Investments in property, plant and equipment | -$-150K | -$-3.05M | -$-840K | -$-1.86M | -$-1.8M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-3.05M | -$-710K |
| Net cash used for investing activities | -$-830K | -$-1.81M | -$-3.75M | -$-3.35M | -$-4.02M |
| Common stock issued | $0.00 | $3.84M | $0.00 | $1.85M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $0.00 | $3.84M | $0.00 | $1.85M | $0.00 |
| Net change in cash | $260K | $290K | -$-3.97M | -$-2.39M | -$-1.16M |
| Cash at end of period | $8.1M | $7.84M | $7.55M | $11.5M | $13.9M |
| Operating cash flow | $850K | -$-1.47M | $50K | -$-660K | $2.86M |
| Capital expenditure | -$-150K | -$-3.05M | -$-840K | -$-1.86M | -$-1.8M |
| Free cash flow | $690K | -$-4.52M | -$-790K | -$-2.52M | $1.06M |
Line items
Line items
Line items
About Zhongchao Inc.
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
- CEO
- Weiguang Yang
- Employees
- 33
- Beta
- -0.01
Explore
Frequently asked questions
What is the intrinsic value of Zhongchao Inc. (ZCMD)?
InvestorsCraft does not currently publish an intrinsic value for ZCMD. How the IC value is calculated.
Is ZCMD undervalued?
InvestorsCraft does not publish an undervaluation signal for ZCMD at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.